CN104490958A - Application of radix bupleuri in preparation of medicines for preventing and treating ionizing radiation injuries - Google Patents

Abstract

The invention relates to the field of medicines, discloses an application of radix bupleuri in preparation of medicines for preventing and treating ionizing radiation injuries, and discloses an application of a total extract of honewort or bupleurum scorzonerifolium in preparation of medicines for preventing and treating the ionizing radiation injuries. A radix bupleuri extract disclosed by the invention plays a radiation protection role in cellular level and animal living level, and plays a protective role under wide dosage ranges of lethal dosage, sub-lethal dosage and low irradiation dosage; and the radix bupleuri extract is stable in quality, low in cost, and wide in source, and can be applied to preparation of medicines for treatment of related injuries caused by ionizing radiation and disease treatment.

Description

The application in prevention and therapy ionization radiation injury medicine prepared by Radix Bupleuri

Relate to field

The present invention relates to field of medicaments, be specifically to extract and the application of next effective ingredient in the associated injury treatment caused for the preparation of prevention and therapy ionizing radiation and disease treatment from Radix Bupleuri or Radix Bupeuri Scorzonerfolii..

Background technology

Flourish along with global core cause, nuclear technology is in every field extensive uses such as nuclear power station, aerospace industry, national defence and biological medicines, human contact's ionizing radiation also causes the chance damaged to increase, the nuclear war simultaneously brought along with world's nuclear safety situation is nervous and nuclear terrorism secret worry, the protection of the body injury (referred to as radiation damage) that ionizing radiation causes is being subject to increasing attention with treatment.

On the other hand, the sickness rate of malignant tumor and patient populations are in recent years always in the trend continuing to rise, radiotherapy is as one of essential therapeutic arsenals, play a part indispensable, but high dose radiation irradiates the acute radiation injury of tumor surrounding normal tissue and organ and even the whole body that can cause unavoidably, the side reaction that radiation damage brings seriously limits the extensive use of radiotherapy in oncotherapy, also obviously have impact on the quality of life after tumor patient Radiotherapy and treatment.

The radiation damage treatment related drugs of putting on market at present mainly contains: sulfur-containing compound, hormones, cytokine class and Chinese herbal medicine etc., there is respective inherent shortcoming in them: the general side effect of such as sulfur-containing compound larger respectively, amifostine (having another name called amifostine) is the best compound of the protection effect of generally acknowledging at present as the representative of this compounds, it is international managing body pass through first selectively wide spectrum cytoprotective, but half-life extremely short (7 minutes) and expensive (domestic medical market price 400-500 unit /) limit its application, and hormone medicine to the control of radiation damage mainly to bone marrow nucleated cell, hematopoietic stem cell and CFU-GM, the impact of this type of medicine on sexual organ and reproductive system limits widely using of it, the hemopoietic function of bone marrow system injury that radiation causes can be alleviated and give treatment to cytokine class medicine such as interleukin class, colony stimulating factor class medicine, but its Study On The Radioprotective and administration time closely related (in the medical practice for preventing and give treatment to, this type of medicine requires high to medical care detection level and degree of concern), there is obvious proinflammatory effect, and expensive, be difficult to room temperature and preserve, Chinese herbal medicine class radioprotective composition mainly contains phenols, polysaccharide, natural flavonoid, has the features such as active component is indefinite, low toxicity, studies through for many years, so far without listing or similar drugs to be gone on the market.

The present invention relates to the novelty teabag of Radix Bupleuri or Radix Bupeuri Scorzonerfolii. total extract, be called Radix Bupleuri extract, composition comprises saikoside, sterol (bupleurumol, eugenol etc.), flavonoid, lignanoids, coumarin and polysaccharide etc., clinical injection of Radix Bupleuri used is Radix Bupleuri total extract, water extraction method, has antipyretic-antalgic, antiinflammatory, antiviral, Nnti-Bacterial endotoxin effect.But up to now, to Radix Bupleuri for the preparation of prevention and therapy ionization radiation injury treatment and tumour radiotherapy ancillary drug in application there is not been reported.

Summary of the invention

The object of this invention is to provide the novelty teabag of Radix Bupleuri.

The novelty teabag of Radix Bupleuri provided by the present invention is: for the preparation of the treatment of prevention and therapy ionization radiation injury and the application of tumour radiotherapy ancillary drug aspect.

Ionization radiation injury of the present invention comprises fatal dose irradiation, sublethal dose and low dose exposure damage, also comprises the radiation damage that tumour radiotherapy produces.

The present invention adopts the existing injection of Radix Bupleuri in market, also uses the Radix Bupleuri water extract extracted voluntarily.The invention provides the novelty teabag of Radix Bupleuri, its type of service, according to clinical needs, corresponding adjuvant can be added, exist with dosage forms such as tablet, pill, capsule, suspension, solution, syrup, injection, solvent, cream, ointment, sprays.

The using dosage of Radix Bupleuri novelty teabag provided by the present invention 1-100mg/Kg body weight (people), but is not limited thereto scope.

Objects and advantages of the present invention are by for illustration and explanation by the non-limitative illustration of following preferred embodiments, and these embodiments provide as an example with reference to accompanying drawing.

Accompanying drawing explanation

Fig. 1 Radix Bupleuri significantly improves C57 Mus fatal dose and irradiates (χ roentgenization: Fig. 1 a, gamma-rays irradiation: natural law of Fig. 1 b) surviving afterwards.

Fig. 2 Radix Bupleuri significantly improves C57 Mus Sublethal Doses (9Gy gamma-rays) and irradiates latter 30 days survival rates.

Fig. 3 Radix Bupleuri irradiates the Hemoprotection of the radiation damage caused to low dosage (5Gy gamma-rays).

Fig. 4 Radix Bupleuri is to the radiate protective action of MCF-7 Human Breast Cancer Cells (cytological map, 1. matched group under microscope; 2. irradiation group; 3. Radix Bupleuri 1mg/ml; 4. irradiation+Radix Bupleuri 1mg/ml).

Detailed description of the invention

Embodiment one

Single fatal dose (13Gy χ ray/gamma-rays) irradiates the radiation damage treatment caused

Injection of Radix Bupleuri, can prepare voluntarily with reference to published patent of invention description or pertinent literature, also can buy in medical market, administering mode is lumbar injection, and dosage is 200mg/Kg, 400mg/Kg body weight (Mus).

χ beam exposure apparatus X-Rad RS-2000 irradiation instrument, voltage 160KV, band radiation energy is 50KeV, close rate 1.01Gy/min.

Gamma-rays irradiation unit ¹³⁷cs irradiation instrument, close rate 0.5Gy/min.

C57BL/6 mice, male and female half and half, body weight 18-20g, quality certification SCXK (capital) 2012-0001, grouping situation is: do not irradiate group, irradiation to normal saline group, irradiation to Radix Bupleuri group, often organize 10.

Adopt single fatal dose 13Gy total irradiation, dosage regimen is pre-irradiation 30 minutes intraperitoneal administrations, supplements immediately and is administered once, within every 24 hours afterwards, be administered once, continuous 14 days after irradiation.

Testing index: survival natural law.

Experimental result is shown in Fig. 1, Radix Bupleuri can significant prolongation fatal dose irradiate after time-to-live of C57 Mus.

Embodiment two

Sublethal dose (9Gy gamma-rays) irradiates the radiation damage treatment caused

Medicine information, animal information, irradiation devices and parameter, administering mode are identical with embodiment one.

Exposure dose is 9Gy.

Testing index: 30 days survival rates.

Experimental result is shown in Fig. 2, and Radix Bupleuri can significantly improve the survival rate of C57 Mus after Sublethal Doses.

Embodiment three

Low dosage (5Gy gamma-rays) irradiates the Hemoprotection of the radiation damage caused

Medicine information, animal information, irradiation devices and parameter, administering mode are identical with embodiment one.

Exposure dose is 5Gy.

Testing index: body weight, peripheral blood counting, one-sided femur counting, CFU-GM, index and spleen index, thymus index.

Experimental result is shown in Fig. 3, and Radix Bupleuri significantly can alleviate the animal hemopoietic system damage that low dose exposure causes.

Embodiment four

Radix Bupleuri is to kinds of tumor cells/Normocellular radiation (gamma-rays) protective effect

Injection of Radix Bupleuri, Kang Hua Medicine stock Co., Ltd of Henan Province, the accurate word Z41021736 of traditional Chinese medicines, lot number 13102201.

Irradiation devices are identical with embodiment one with parameter.

Cell line adopts MCF-7 Breast Cancer Cell, breast carcinoma MDA-MB-231 cell, hepatoma Hep G 2 cells, lung cancer A549 cell, Human Embryonic Kidney HEK 293 cell, people's microvascular endothelial HMEC-1 cell.

Experimentation:

1. cell line and cultivation

Adopt human hepatoma HepG2 cell, typeⅡ pneumocyte, respectively with containing 10%FBS (Gibico, REF10099-141), containing 100 μ g/ml streptomycins and 100U/ml penicillin, DMEM in high glucose (Hyclone, SH30243.01B) and PRMI1640 (Hyclone, SH30809.01B) cultivate, be placed in 37 DEG C, 5%CO ₂constant incubator in routine passage cultivate.

2. drug treating and irradiation

Cell culture, to exponential phase, changes the culture fluid containing variable concentrations medicine, continues cultivation 24 hours, accepts various dose gamma-rays and irradiates.

3. colony formation

After cell irradiation, inoculate different cell quantity by different exposure doses and be inoculated into 60mm culture dish.Cell continuous culture was fixed with methanol after 3 weeks, and add Ji's nurse Sa application liquid and dye 30 minutes, flowing water is cleaned, clone's number of counting cells number >=50.Cloning efficiency and surviving fraction is calculated by cloning efficiency PE=(matched group clone number/experimental group cell number) × 100% and surviving fraction=clone's number/(experimental group cell number × PE).And click models fitting drafting cell survival curve by many targets.

Testing index: IC ₅₀(killing the radiological dose of 50% cell)

Experimental result is shown in Fig. 4 and table 1, and Radix Bupleuri can improve kinds of tumor cells or Normocellular radiation tolerance dose, has certain radiate protective action.

Table 1 Radix Bupleuri irradiates IC to kinds of tumor cells/normal cell gamma-rays irradiating gamma-ray ₅₀impact (Gy)

Comprehensive above embodiment result, explanation the invention has the advantages that:

Radix Bupleuri can play radiate protective action in cellular level and living animal level, and under radiation dose range widely, all has protective effect, can be used for the treatment of prevention and therapy ionization radiation injury and tumour radiotherapy ancillary drug.

Claims (5)

1. the application in prevention and therapy ionization radiation injury treatment medicine prepared by Radix Bupleuri.

2. application according to claim 1, wherein said ionization radiation injury treatment includes but not limited to that single fatal dose irradiates the acute ionization radiation injury treatment caused.

3. application according to claim 1, wherein said ionization radiation injury treatment includes but not limited to that the hemopoietic system damage that single/repeatedly low dose exposure causes is given treatment to.

4. the application in tumour radiotherapy ancillary drug prepared by Radix Bupleuri.

5. application according to claim 4, wherein said tumour radiotherapy includes but not limited to breast carcinoma.